Executive level Marketing and Public Policy professional with over 20 years experience leading transformational change in the healthcare public and private sectors. Results-oriented leader, with a proven track record in building and mobilizing high performance teams to deliver break-through solutions that successfully impact business results. Demonstrated expertise in shaping government and commercial policies that reward pharmaceutical innovation, drive appropriate market access and maintain a competitive, free market healthcare system. Accomplished presenter and persuasive communicator with proven ability to engage internal and external stakeholders to foster public/private partnerships

Vice President, Public Policy @ Lead the US Public Policy and Reimbursement team for NA Pharma. Responsible for diagnosing the federal/state governments’ impact on GSK’s market access strategy, and executing legislative, regulatory and public payer initiatives to advance US business priorities. Direct the implementation of GSK’s 6 healthcare reform priorities, including the development of an enterprise-wide quality strategy, advancing real world evidence communication, and executing the LOC public/private market access plan. Drive public and commercial policies that support the launch and pull through of priority assets - shaping government regulations to encourage and reward innovation and facilitate appropriate patient coverage. As the lead for the company’s medical countermeasure strategy, direct GSK’s global biosecurity matrix team and US government engagement plan. Significant Accomplishments: • Expanded access to Tdap vaccine by shifting coverage from Medicare Part D to Part B for diabetics/wound management • Implemented Medicare patient access strategy to limit government pricing/interference in $3.2b business • Implemented new Public Policy platform to drive GSK US reputation position: innovation, collaboration and access • Secured government and stakeholder commitment to developing an adult vaccine quality set • Shaped regulation to include a tier 6 benefit design to broaden Medicare market access for adult vaccines • Ensured patient protections in public programs by defeating regulation to reduce Medicare “Protected Classes” • Reengineered NGO grants process to drive “Value of Vaccines” mission within US compliance guidelines • Developed and executed GSK global biosecurity strategy, managing $1.2b in annualized US government contracts From September 2006 to Present (9 years 2 months) Philadelphia. PaVice President, Marketing @ Marketing Officer for a national healthcare company’s $7.1B middle market employer segment. Reporting to the Chief Marketing Officer, led the strategic planning, marketing and distribution strategies for Cigna’s 28 local healthcare markets. Managed a national field-based marketing organization to successfully meet the segment’s revenue, member enrollment and profits goals. Responsible for national and local market business development, research, public relations, marketing and product development. Significant Accomplishments • Drove aggressive growth turnaround strategy in 10 select markets, netting 15% Middle Market membership growth. • Implemented customer retention strategies for top 250 at-risk accounts, raising retention level to 91% • Stabilized membership in all major markets, reversing 3-year trend in membership decline • Developed preferred-producer sales strategy, creating 13% increase in RFP activity. • Implemented national sales post-mortem analysis to identify key drivers of attrition, improving close ratios by 18% • Developed and launched Consumer Directed Health Plan product in 28 markets. From January 1990 to March 2005 (15 years 3 months)

Bachelor of Arts (B.A.), English @ Colby College